Cerevel Therapeutics Holdings, Inc.
CERE
주식 순위
#2804
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
주가
$44.96
마지막 동기화: 2024-08-01
시가총액
$6.67B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Cerevel Therapeutics Holdings, Inc. (CERE)
카테고리
Healthcare
Cerevel Therapeutics Holdings, Inc. (CERE)의 EPS
March 2024 기준 EPS TTM: $-2.73
Cerevel Therapeutics Holdings, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-2.73입니다. 2022년 말에는 회사의 EPS가 $-2.32였으며, 이는 2021년의 EPS $-1.63와 증가입니다.
Cerevel Therapeutics Holdings, Inc.의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-2.73 | 2.25% |
| 2023 | $-2.67 | 15.09% |
| 2022 | $-2.32 | 42.33% |
| 2021 | $-1.63 | 26.36% |
| 2020 | $-1.29 | 27.72% |
| 2019 | $-1.01 | -84.60% |
| 2018 | $-6.56 | 231.31% |
| 2015 | $-1.98 | -3.88% |
| 2014 | $-2.06 | -9.65% |
| 2013 | $-2.28 | 10.14% |
| 2012 | $-2.07 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -734.43% |
US
|
|
| $-7.98 | 192.31% |
US
|
|
| $-5.29 | 93.77% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,116.12% |
NL
|
